Microscopy Image Analysis Patents: Leaders, Trends & White Space 2026
- Concentration is moderate, not locked. the top 5 assignees hold 19.7% of all 985 records and the top 10 hold 33.2% — a wide field still open to new entrants.
- Filing kept climbing through 2024. the last complete year, up 46% from 2021's 79 filings to 2024's 115, before the expected 18-month publication lag thins 2025-2026.
- Segmentation claims sit inside a genomics-heavy IPC mix. G01N and C12Q/C12N appear alongside G06T and G06V, meaning image-processing claims are frequently bundled with wet-lab and diagnostic method claims.
Filing growth compares 2021 (79 records) with 2024 (115) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 985 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks 985 published records filed between 2015 and mid-2026 that combine microscopy image analysis or cell segmentation language with technical claims around deep learning segmentation, annotation burden, batch processing, reproducibility, file format handling, or compute requirements. The scope spans both the image-processing side of the pipeline and the biological or diagnostic application it feeds — which is why classes like C12Q and A61K show up alongside G06T and G06V.
Records here range from foundational segmentation algorithms through to pipeline infrastructure claims covering annotation tooling, batch throughput and file-format interoperability. Because publication lags filing by roughly 18 months, the 2025-2026 counts are still filling in and should not be read as a slowdown.
Filing trend and technology composition
Two views of the same 985-record set: filings by year, and the IPC subclasses those filings carry.
Filings climbed steadily to a 2024 peak
Annual filings rose from 54 in 2017 to a peak of 115 in 2024, including a 46% jump from 79 filings in 2021 to 115 in 2024. The 2025 and 2026 figures (down to 12 for the partial year) reflect publication lag, not falling interest.
Image processing claims are bundled with wet-lab and diagnostic classes
G01N (30.2% of records) and G06T (28.4%) are the two largest classes, with G06V close behind at 20.0%. C12Q and C12N together show that a large share of segmentation claims are written into genomic or cellular assay contexts rather than as pure image-processing inventions, and A61K/A61P confirm many pipelines are drafted with a therapeutic or diagnostic end-use in the claim set.
Shares are the percentage of the 985 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Microscopy Image Analysis Pipelines with Eureka
This page is one run against one query. Ask Eureka your own question about microscopy image analysis pipelines and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited prior art
WO2025029788A1 — Systems and methods for image-based cell segmentation, cell division detection, and cell tracking
The present application provides methods and systems for image-based cell segmentation detection, image-based cell division detection, and image based cell tracking comprising receiving image data and applying machine learning algorithms to extract cell segments, division events, and cell tracks through images.Filed by Cairn Biosciences, published February 2025 — illustrates the current claim style: a single pipeline spanning segmentation, event detection and tracking rather than a standalone segmentation algorithm.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5533021A | Apparatus and method for segmentation and time synchronization of the transmission of multimedia data | 567 |
| 2 | US5537408A | apparatus and method for segmentation and time synchronization of the transmission of multimedia data | 384 |
| 3 | US5652749A | Apparatus and method for segmentation and time synchronization of the transmission of a multiple program mult… | 351 |
| 4 | US20010009604A1 | Digital video recording system and its recording medium | 262 |
| 5 | US20200258223A1 | Determining biomarkers from histopathology slide images | 239 |
| 6 | WO2018026873A1 | Sequential probing of molecular targets based on pseudo-color barcodes with embedded error correction mechani… | 183 |
| 7 | WO2012049316A1 | Dynamic range methods | 180 |
| 8 | US5732150A | Method and system for multiple wavelength microscopy image analysis | 177 |
| 9 | US20020186875A1 | Computer methods for image pattern recognition in organic material | 174 |
| 10 | WO2017143155A2 | Multiplex alteration of cells using a pooled nucleic acid library and analysis thereof | 162 |
Citation counts reward older, foundational filings — several of the most-cited records here predate modern deep-learning segmentation and are cited for general multimedia segmentation and synchronization concepts rather than microscopy-specific methods.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for strategy
Three read-outs from the concentration, growth and citation data that matter for a filing or freedom-to-operate decision.
No single assignee dominates the space
The leader holds 49 records and fifth place holds 30 — a meaningful gap, but not a chokehold. With the top 5 controlling only 19.7% of all 985 records and the top 10 at 33.2%, most of the field is held by assignees with far smaller portfolios, which leaves room for a well-drafted pipeline patent to stand out rather than compete directly with an incumbent's claim thicket.
Filing activity is still expanding, not plateauing
Annual filings grew from 79 in 2021 to 115 in 2024, the last year that can be treated as complete given typical publication lag. That trajectory suggests active claim-staking is ongoing rather than settled, so a freedom-to-operate search done today should assume more filings from the 2024-2025 window will still surface as they publish.
Heavily-cited prior art is not microscopy-specific
The most-cited records in this corpus are general multimedia segmentation and synchronization patents from the 1990s, not microscopy image analysis inventions. That means citation count alone is a poor filter for technical relevance here — it favours old, broadly-drafted priority documents over the newer, domain-specific pipeline claims that actually define current freedom-to-operate risk.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to microscopy image analysis pipelines, with the prior art for and against each one.
Who is filing, and where momentum has cooled
The ranked list spans large research institutions, diagnostics companies and genomics platform providers, with several leading names showing no filings in the latest tracked year — consistent with the publication lag rather than a retreat from the space.
Academic and institutional assignees anchor the top of the ranking
The leading assignee's 49 records and the presence of major universities and public research institutes among the top ranks reflect how much of this field originates in academic labs before licensing or spinning out into diagnostics and genomics companies.
Co-assignee pairs point to institute-industry collaboration
Ten co-assignee pairs appear in the data, with the strongest pairings linking major research institutes to affiliated research bodies — a pattern typical of translational genomics and histopathology programmes that file jointly rather than through a single corporate entity.
Recent-year momentum has cooled for early leaders
Several of the most active historical filers show zero filings in the latest tracked year, including some with a full year-over-year drop. Given the 18-month publication lag, this is best read as a data-visibility gap rather than firms exiting the space.
| Assignee | Recent year | YoY |
|---|---|---|
| President and Fellows of Harvard College | 0 | — |
| TEMPUS LABS INC | 0 | — |
| 10x Genomics, Inc. | 0 | -100% |
| Abbott Laboratories | 0 | — |
| Institut National de la Santé et de la Recherche Médicale (INSERM) | 0 | -100% |
| Massachusetts Institute of Technology | 0 | — |
| The General Hospital Corporation | 0 | -100% |
| The Broad Institute, Inc. | 0 | — |
Where to take this analysis
The dataset points to a field with room at the edges even as the core segmentation claims thicken.
Run a freedom-to-operate check on pipeline infrastructure claims
Annotation burden, batch processing and file-format interoperability show thinner claim density than core segmentation — worth a targeted search before drafting in those areas.
Explore with Eureka →Track the 2024-2025 filing wave as it publishes
With 2024 filings up 46% on 2021 and publication lag still filling in 2025-2026, re-running this search in six months will surface filings not yet visible today.
Set up monitoring in Eureka →Common questions about this landscape
The ranking covers 100 assignees drawn from 985 records, with the leader holding 49 records and the fifth-ranked assignee holding 30. The top 5 assignees combined account for 19.7% of all records in scope, and the top 10 account for 33.2% — meaningful but not dominant concentration. That leaves the majority of filings spread across a long tail of smaller assignees, including diagnostics companies, genomics platforms and academic research institutions.
Yes, through the most recent complete year. Filings rose from 79 in 2021 to 115 in 2024, a 46% increase, and the overall trend from 2017's 54 filings shows sustained growth rather than plateau. The apparent drop-off in 2025-2026 is a publication-lag artifact — patents typically publish around 18 months after filing, so those years are still filling in and should not be read as declining interest.
G01N (material analysis and testing) and G06T (image data processing) are the two largest classes, covering 30.2% and 28.4% of the 985 records respectively, with G06V (image and video recognition) close behind at 20.0%. Notably, C12Q and C12N — enzyme/DNA measurement and genetic engineering — also appear in a substantial share of records, showing that many segmentation pipelines are claimed in the context of genomic or cellular assays rather than as standalone image-processing methods.
The evidence points to thinner claim density in pipeline-infrastructure areas: annotation burden reduction tooling, cross-platform file format interoperability, batch processing throughput, reproducibility validation methods, and compute requirement optimization for edge or low-resource deployment. These are documented search terms in this dataset but sit behind the core segmentation and detection claims in filing volume, suggesting room for narrowly scoped infrastructure patents that don't compete directly with the dense segmentation art.
Treat them cautiously. The most-cited records in this corpus are 1990s-era multimedia segmentation and synchronization patents cited for general concepts, not microscopy-specific inventions — a reminder that citation counts inside any searched corpus favour older, broadly drafted documents over newer domain-specific ones. For assessing current technical relevance or freedom-to-operate risk, recency and claim scope matter more than raw citation totals.
Research Microscopy Image Analysis Pipelines in depth with Eureka
Go past this page: query the whole microscopy image analysis pipelines corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.